Which has preferable earnings and valuation, DCTH or CDRE?

Cadre has higher revenue and earnings than Delcath Systems. Cadre is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Delcath Systems $85.23M 4.32 $2.70M $0.01 1,067.00 Cadre $610.31M 2.10 $44.14M $0.89 33.60

Is DCTH or CDRE more profitable?

Cadre has a net margin of 5.80% compared to Delcath Systems' net margin of 0.62%. Cadre's return on equity of 12.39% beat Delcath Systems' return on equity. Company Net Margins Return on Equity Return on Assets Delcath Systems 0.62% 0.51% 0.46% Cadre 5.80% 12.39% 5.08%

Is ENOV or DCTH more profitable?

Delcath Systems has a net margin of 0.62% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Delcath Systems' return on equity. Company Net Margins Return on Equity Return on Assets Enovis -49.92% 10.32% 4.57% Delcath Systems 0.62% 0.51% 0.46%

Delcath Systems (DCTH) Competitors

$10.67 -0.12 (-1.11%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$10.76 +0.10 (+0.89%)

As of 06/5/2026 07:37 PM Eastern

Compare

DCTH vs. EYE, CDRE, ENOV, KMTS, and BLFS

Should you buy Delcath Systems stock or one of its competitors? MarketBeat compares Delcath Systems with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Delcath Systems include National Vision (EYE), Cadre (CDRE), Enovis (ENOV), Kestra Medical Technologies (KMTS), and BioLife Solutions (BLFS). These companies are all part of the "medical equipment" industry.

How does Delcath Systems compare to National Vision?

Delcath Systems (NASDAQ:DCTH) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Delcath Systems currently has a consensus target price of $22.50, suggesting a potential upside of 110.87%. National Vision has a consensus target price of $30.08, suggesting a potential upside of 94.84%. Given Delcath Systems' higher probable upside, research analysts clearly believe Delcath Systems is more favorable than National Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

61.1% of Delcath Systems shares are held by institutional investors. 19.4% of Delcath Systems shares are held by insiders. Comparatively, 2.4% of National Vision shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

National Vision has a net margin of 2.31% compared to Delcath Systems' net margin of 0.62%. National Vision's return on equity of 6.41% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
National Vision	2.31%	6.41%	2.81%

In the previous week, National Vision had 2 more articles in the media than Delcath Systems. MarketBeat recorded 2 mentions for National Vision and 0 mentions for Delcath Systems. National Vision's average media sentiment score of 0.95 beat Delcath Systems' score of 0.00 indicating that National Vision is being referred to more favorably in the news media.

Company	Overall Sentiment
Delcath Systems	Neutral
National Vision	Positive

National Vision has higher revenue and earnings than Delcath Systems. National Vision is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	4.32	$2.70M	$0.01	1,067.00
National Vision	$1.99B	0.62	$29.60M	$0.57	27.09

Delcath Systems has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, National Vision has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Summary

National Vision beats Delcath Systems on 11 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to Cadre?

Delcath Systems (NASDAQ:DCTH) and Cadre (NYSE:CDRE) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

In the previous week, Cadre had 6 more articles in the media than Delcath Systems. MarketBeat recorded 6 mentions for Cadre and 0 mentions for Delcath Systems. Cadre's average media sentiment score of 0.61 beat Delcath Systems' score of 0.00 indicating that Cadre is being referred to more favorably in the news media.

Company	Overall Sentiment
Delcath Systems	Neutral
Cadre	Positive

Cadre has a net margin of 5.80% compared to Delcath Systems' net margin of 0.62%. Cadre's return on equity of 12.39% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
Cadre	5.80%	12.39%	5.08%

Cadre has higher revenue and earnings than Delcath Systems. Cadre is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	4.32	$2.70M	$0.01	1,067.00
Cadre	$610.31M	2.10	$44.14M	$0.89	33.60

Delcath Systems has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Cadre has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Delcath Systems currently has a consensus price target of $22.50, indicating a potential upside of 110.87%. Cadre has a consensus price target of $39.75, indicating a potential upside of 32.94%. Given Delcath Systems' higher possible upside, equities research analysts plainly believe Delcath Systems is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cadre	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 44.0% of Cadre shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by insiders. Comparatively, 30.1% of Cadre shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cadre beats Delcath Systems on 12 of the 17 factors compared between the two stocks.

How does Delcath Systems compare to Enovis?

Enovis (NYSE:ENOV) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Enovis had 9 more articles in the media than Delcath Systems. MarketBeat recorded 9 mentions for Enovis and 0 mentions for Delcath Systems. Enovis' average media sentiment score of 0.40 beat Delcath Systems' score of 0.00 indicating that Enovis is being referred to more favorably in the media.

Company	Overall Sentiment
Enovis	Neutral
Delcath Systems	Neutral

98.5% of Enovis shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 2.9% of Enovis shares are owned by insiders. Comparatively, 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Delcath Systems has a net margin of 0.62% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
Delcath Systems	0.62%	0.51%	0.46%

Delcath Systems has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.61	-$1.18B	-$19.88	N/A
Delcath Systems	$85.23M	4.32	$2.70M	$0.01	1,067.00

Enovis presently has a consensus price target of $44.50, suggesting a potential upside of 87.38%. Delcath Systems has a consensus price target of $22.50, suggesting a potential upside of 110.87%. Given Delcath Systems' higher possible upside, analysts clearly believe Delcath Systems is more favorable than Enovis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Enovis has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Summary

Enovis beats Delcath Systems on 9 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Kestra Medical Technologies currently has a consensus target price of $27.40, indicating a potential upside of 41.24%. Delcath Systems has a consensus target price of $22.50, indicating a potential upside of 110.87%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Kestra Medical Technologies has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

61.1% of Delcath Systems shares are held by institutional investors. 3.6% of Kestra Medical Technologies shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Kestra Medical Technologies had 1 more articles in the media than Delcath Systems. MarketBeat recorded 1 mentions for Kestra Medical Technologies and 0 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 0.00 beat Kestra Medical Technologies' score of -0.36 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Overall Sentiment
Kestra Medical Technologies	Neutral
Delcath Systems	Neutral

Delcath Systems has higher revenue and earnings than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$59.81M	18.93	-$113.81M	-$3.96	N/A
Delcath Systems	$85.23M	4.32	$2.70M	$0.01	1,067.00

Delcath Systems has a net margin of 0.62% compared to Kestra Medical Technologies' net margin of -171.87%. Delcath Systems' return on equity of 0.51% beat Kestra Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-171.87%	-65.49%	-46.39%
Delcath Systems	0.62%	0.51%	0.46%

Summary

Delcath Systems beats Kestra Medical Technologies on 13 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

In the previous week, BioLife Solutions had 9 more articles in the media than Delcath Systems. MarketBeat recorded 9 mentions for BioLife Solutions and 0 mentions for Delcath Systems. BioLife Solutions' average media sentiment score of 0.07 beat Delcath Systems' score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
BioLife Solutions	Neutral
Delcath Systems	Neutral

BioLife Solutions has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Delcath Systems has a net margin of 0.62% compared to BioLife Solutions' net margin of -2.80%. BioLife Solutions' return on equity of 1.81% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-2.80%	1.81%	1.65%
Delcath Systems	0.62%	0.51%	0.46%

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioLife Solutions currently has a consensus price target of $32.00, suggesting a potential upside of 20.08%. Delcath Systems has a consensus price target of $22.50, suggesting a potential upside of 110.87%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts plainly believe Delcath Systems is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Delcath Systems has lower revenue, but higher earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	13.53	-$4.59M	-$0.08	N/A
Delcath Systems	$85.23M	4.32	$2.70M	$0.01	1,067.00

Summary

BioLife Solutions and Delcath Systems tied by winning 8 of the 16 factors compared between the two stocks.

Get Delcath Systems News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCTH vs. The Competition

Export

Metric	Delcath Systems	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$368.35M	$7.25B	$6.68B	$11.99B
Dividend Yield	N/A	1.20%	2.67%	5.55%
P/E Ratio	1,067.00	45.87	24.06	23.63
Price / Sales	4.32	73.75	516.17	112.20
Price / Cash	204.12	24.67	42.23	54.60
Price / Book	3.39	6.95	9.73	6.35
Net Income	$2.70M	$159.22M	$3.57B	$337.59M
7 Day Performance	-1.02%	-2.59%	-1.28%	-2.52%
1 Month Performance	-5.07%	1.84%	1.38%	-0.03%
1 Year Performance	-34.86%	-1.02%	23.93%	25.34%

Delcath Systems Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCTH Delcath Systems	1.927 of 5 stars	$10.67 -1.1%	$22.50 +110.9%	-34.9%	$368.35M	$85.23M	1,067.00	60	Gap Up
EYE National Vision	4.5468 of 5 stars	$15.87 -5.2%	$30.08 +89.5%	-26.6%	$1.34B	$2.02B	28.11	13,138
CDRE Cadre	4.6389 of 5 stars	$30.12 -3.3%	$39.75 +32.0%	-13.4%	$1.31B	$635.63M	34.08	2,533	Analyst Upgrade
ENOV Enovis	4.5033 of 5 stars	$21.47 -5.3%	$44.50 +107.3%	-25.3%	$1.25B	$2.28B	N/A	7,802	News Coverage Analyst Downgrade Gap Down
KMTS Kestra Medical Technologies	2.2049 of 5 stars	$19.24 -9.5%	$27.40 +42.4%	-6.3%	$1.24B	$59.81M	N/A	300	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCTH) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Delcath Systems (DCTH) Competitors

DCTH vs. EYE, CDRE, ENOV, KMTS, and BLFS

How does Delcath Systems compare to National Vision?

Summary

How does Delcath Systems compare to Cadre?

Summary

How does Delcath Systems compare to Enovis?

Summary

How does Delcath Systems compare to Kestra Medical Technologies?

Summary

How does Delcath Systems compare to BioLife Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Delcath Systems (DCTH) Competitors

DCTH vs. EYE, CDRE, ENOV, KMTS, and BLFS

How does Delcath Systems compare to National Vision?

Do analysts prefer DCTH or EYE?

Do institutionals and insiders hold more shares of DCTH or EYE?

Is DCTH or EYE more profitable?

Does the media refer more to DCTH or EYE?

Which has preferable earnings & valuation, DCTH or EYE?

Which has more risk and volatility, DCTH or EYE?

Summary

How does Delcath Systems compare to Cadre?

Does the media prefer DCTH or CDRE?

Is DCTH or CDRE more profitable?

Which has preferable earnings and valuation, DCTH or CDRE?

Which has more volatility and risk, DCTH or CDRE?

Do analysts rate DCTH or CDRE?

Do institutionals & insiders believe in DCTH or CDRE?

Summary

How does Delcath Systems compare to Enovis?

Does the media prefer ENOV or DCTH?

Do institutionals and insiders hold more shares of ENOV or DCTH?

Is ENOV or DCTH more profitable?

Which has better valuation & earnings, ENOV or DCTH?

Do analysts rate ENOV or DCTH?

Which has more volatility & risk, ENOV or DCTH?

Summary

How does Delcath Systems compare to Kestra Medical Technologies?

Do analysts rate KMTS or DCTH?

Which has more volatility and risk, KMTS or DCTH?

Do insiders & institutionals have more ownership in KMTS or DCTH?

Does the media prefer KMTS or DCTH?

Which has higher valuation & earnings, KMTS or DCTH?

Is KMTS or DCTH more profitable?

Summary

How does Delcath Systems compare to BioLife Solutions?

Does the media favor BLFS or DCTH?

Which has more volatility & risk, BLFS or DCTH?

Is BLFS or DCTH more profitable?

Do insiders & institutionals hold more shares of BLFS or DCTH?

Do analysts recommend BLFS or DCTH?

Which has better valuation and earnings, BLFS or DCTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools